Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Conroy

Showing results (121-130 of 138) with videos related to

Pageof 14
Sort By:
British Journal of Cancer|January 11, 2014
Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trialE Samalin, O Bouché, S Thézenas, et al.
Toxicology Letters|January 26, 2021
Dose-dependent emergence of acute and recurrent corneal lesions in sulfur mustard-exposed rabbit eyesPatrick M McNutt, Kyle E M Kelly, Amber C Altvater, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 10, 2024
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trialT Conroy, F Castan, P-L Etienne, et al.
European Journal of Cancer (Oxford, England : 1990)|September 27, 2005
An international prospective study of the EORTC cancer in-patient satisfaction with care measure (EORTC IN-PATSAT32)A Brédart, A Bottomley, J M Blazeby, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1997
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapyP Rougier, R Bugat, J Y Douillard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 25, 2020
Corrigendum to An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45: Ann Oncol 2020; Volume 31, Issue 2, Pages 283-288V Bjelic-Radisic, F Cardoso, D Cameron, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45V Bjelic-Radisic, F Cardoso, D Cameron, et al.
European Journal of Cancer (Oxford, England : 1990)|February 25, 2019
Continuation versus discontinuation of first-line chemotherapy in patients with metastatic squamous cell oesophageal cancer: A randomised phase II trial (E-DIS)A Adenis, J Bennouna, P L Etienne, et al.
Tumori|July 25, 1998
Evaluation of clinical efficacy of new medical treatments in advanced colorectal cancer. Results of a workshop organized by the EORTC GITCCG. European Organization for Research and Treatment of Cancer. Gastrointestinal Tract Cancer Cooperative GroupJ Wils, T Sahmoud, A Sobrero, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancerD Azria, J Doyen, M Jarlier, et al.
Pageof 14

Showing results (121-130 of 138) with videos related to

Sort By:
Pageof 14
British Journal of Cancer|January 11, 2014
Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trialE Samalin, O Bouché, S Thézenas, et al.
Toxicology Letters|January 26, 2021
Dose-dependent emergence of acute and recurrent corneal lesions in sulfur mustard-exposed rabbit eyesPatrick M McNutt, Kyle E M Kelly, Amber C Altvater, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 10, 2024
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trialT Conroy, F Castan, P-L Etienne, et al.
European Journal of Cancer (Oxford, England : 1990)|September 27, 2005
An international prospective study of the EORTC cancer in-patient satisfaction with care measure (EORTC IN-PATSAT32)A Brédart, A Bottomley, J M Blazeby, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1997
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapyP Rougier, R Bugat, J Y Douillard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 25, 2020
Corrigendum to An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45: Ann Oncol 2020; Volume 31, Issue 2, Pages 283-288V Bjelic-Radisic, F Cardoso, D Cameron, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45V Bjelic-Radisic, F Cardoso, D Cameron, et al.
European Journal of Cancer (Oxford, England : 1990)|February 25, 2019
Continuation versus discontinuation of first-line chemotherapy in patients with metastatic squamous cell oesophageal cancer: A randomised phase II trial (E-DIS)A Adenis, J Bennouna, P L Etienne, et al.
Tumori|July 25, 1998
Evaluation of clinical efficacy of new medical treatments in advanced colorectal cancer. Results of a workshop organized by the EORTC GITCCG. European Organization for Research and Treatment of Cancer. Gastrointestinal Tract Cancer Cooperative GroupJ Wils, T Sahmoud, A Sobrero, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancerD Azria, J Doyen, M Jarlier, et al.
Pageof 14